Skip to main navigation
Skip to search
Skip to main content
Augusta University Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at Augusta University Research Profiles
Home
Profiles
Research Units
Scholarly Output
Projects
Datasets
Equipment
Activities
Press/Media
Prizes
Safety of regadenoson in patients with end-stage liver disease
Wael Aljaroudi
, Fahad Iqbal
, Jayanth Koneru
, Pradeep Bhambhvani
, Jaekyeong Heo
, Ami E. Iskandrian
Research output
:
Contribution to journal
›
Article
›
peer-review
28
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety of regadenoson in patients with end-stage liver disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
End-stage Liver Disease
100%
Regadenoson
100%
Safety Profile
25%
Consecutive Patients
12%
Receptor Agonist
12%
Systolic Blood Pressure
12%
Diastolic Blood Pressure
12%
Left Ventricular Ejection Fraction
12%
Tolerability
12%
Liver
12%
Adverse Events
12%
Hospitalization
12%
Hemodynamic Response
12%
Myocardial Perfusion Imaging
12%
Response Profiles
12%
A2A Receptor
12%
Stress Myocardial Perfusion Imaging
12%
Orthotopic Liver Transplantation
12%
Heart Rate Increase
12%
Medication-related
12%
Gated Single-photon Emission Computed Tomography
12%
Vasodilator Stress
12%
Computed Tomography Perfusion
12%
Medicine and Dentistry
End Stage Liver Disease
100%
Regadenoson
100%
Myocardial Perfusion Imaging
37%
Adverse Event
12%
Drug Therapy
12%
Hemodynamic
12%
Diastolic Blood Pressure
12%
Systolic Blood Pressure
12%
Heart Left Ventricle Ejection Fraction
12%
Receptor
12%
Vasodilator Agent
12%
Liver Transplantation
12%
Gated SPECT
12%
Immunology and Microbiology
Heart Muscle Perfusion
100%
Agonist
33%
Hemodynamic
33%
Heart Left Ventricle Ejection Fraction
33%
Systolic Blood Pressure
33%
Diastolic Blood Pressure
33%
Liver Transplantation
33%
Gated Single Photon Emission Computed Tomography
33%
Pharmacology, Toxicology and Pharmaceutical Science
End Stage Liver Disease
100%
Regadenoson
100%
Vasodilator Agent
12%
Adverse Event
12%
Tolerability
12%
Receptor Agonist
12%